CytomX Therapeutics (CTMX) Depreciation & Amortization (CF) (2014 - 2026)

CytomX Therapeutics has reported Depreciation & Amortization (CF) for 13 years, with the latest figure at $214000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 38.68% year-over-year to $214000.0; the trailing twelve-month figure through Mar 2026 stood at $1.1 million (down 28.9% YoY), and the FY2025 full-year result was $1.2 million, down 24.17% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $214000.0, down from $473000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $586000.0 in Q3 2022, with the low at $98000.0 in Q3 2025.
• Historically, Depreciation & Amortization (CF) has averaged $434823.5 across 5 years, with a median of $448000.0 in 2023.
• The largest YoY upside for Depreciation & Amortization (CF) was 25.8% in 2025 against a maximum downside of 75.06% in 2025.
• CytomX Therapeutics' Depreciation & Amortization (CF) stood at $572000.0 in 2022, then dropped by 21.5% to $449000.0 in 2023, then dropped by 16.26% to $376000.0 in 2024, then grew by 25.8% to $473000.0 in 2025, then plunged by 54.76% to $214000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $214000.0 (Q1 2026), $473000.0 (Q4 2025), and $98000.0 (Q3 2025), per Business Quant data.